FDA issues complete response letter to Replimune’s RP1 for melanoma
Replimune’s RP1 is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response.
Therapy Area
ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity
ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D
Non-invasive diagnostics in endometriosis: at the cusp of a turning point
ACC 2026: Baxdrostat lowers BP in uncontrolled hypertension
ACC 2026: Lorundrostat lowers BP but raises hyperkalemia risk
Merck’s strategic shift: acquires Terns for $6.7bn, targeting dominance in CML
Improving early detection and treatment of liver cancer
